ATOS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Atossa Therapeutics Inc (ATOS) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock shows bearish technical indicators, limited positive catalysts, and weak financial performance. While the RSI indicates the stock is oversold, the lack of significant upward momentum and no strong trading signals suggest holding off on investment until more favorable conditions arise.
The stock is showing bearish momentum with the MACD histogram below 0 and negatively contracting. RSI is at 7.039, indicating an oversold condition, but moving averages (SMA_200 > SMA_20 > SMA_5) confirm a bearish trend. Key support is at 2.795, and resistance is at 6.03, suggesting limited upside potential in the short term.
Recent FDA feedback highlights potential expedited pathways for (Z)-endoxifen and significant trial results. The company also received Rare Pediatric Disease designation for (Z)-endoxifen, which may provide future benefits under the Priority Review Voucher program.
The stock price has declined by 2.72% in the regular market and 1.54% in post-market trading. Hedge funds and insiders show neutral sentiment, and there are no significant trading trends. Financial performance remains weak with no revenue growth and negative net income.
In 2025/Q3, revenue remained at 0 with no YoY growth. Net income improved by 20.22% YoY but remains negative at -8.692 million. EPS increased by 17.44% YoY but is still negative at -1.01, indicating ongoing financial struggles.
No recent analyst rating or price target changes were provided. Wall Street sentiment appears neutral, with no significant pros or cons highlighted.
